Olpress-CT 20 Tablet contains a combination of Olmesartan Medoxomil 20 mg and Chlorthalidone 12.5 mg, formulated for the management of hypertension. Olmesartan Medoxomil is an angiotensin II receptor antagonist that selectively inhibits the binding of angiotensin II to the AT1 receptor, thereby reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure. Chlorthalidone is a thiazide-like diuretic that promotes the excretion of sodium and water by inhibiting sodium reabsorption in the distal convoluted tubules of the kidneys, contributing to a reduction in blood volume and peripheral resistance. The combination of these two agents provides complementary mechanisms to effectively control elevated blood pressure, reducing the risk of cardiovascular events such as stroke and myocardial infarction. Olpress-CT 20 is indicated for patients who require multiple antihypertensive agents to achieve optimal blood pressure control. It should be used under medical supervision with appropriate monitoring of renal function, electrolytes, and blood pressure. Caution is advised in patients with renal impairment, electrolyte imbalances, or hypersensitivity to sulfonamide-derived drugs. Adverse effects may include dizziness, hypotension, electrolyte disturbances, and increased urination. This combination therapy enhances patient compliance by simplifying treatment regimens.